Virological profiles in hepatitis B virus inactive carriers: Monthly evaluation in 1-year follow-up study

Liver International

Volumn 25, Issue 3, 2005, Pages 555-563

  Cacciola, Irene ^a   Spatari, Giovanna ^a   Pollicino, Teresa ^a   Costantino, Lucy ^a   Zimbaro, Giovanni ^a   Brancatelli, Santa ^a   Fenga, Concettina ^a   Caccamo, Gaia ^a   Squadrito, Giovanni ^a   Raimondo, Giovanni ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Core promoter mutants; HBV replication; HBV variability; IgM anti HBc; Inactive HBsAg carriage; Precore mutants

Indexed keywords

AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN M; VIRUS DNA;

ADULT; ANTIGEN DETECTION; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; EVALUATION; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENETIC VARIABILITY; HEALTH PRACTITIONER; HEPATITIS B VIRUS; HUMAN; MALE; MOLECULAR CLONING; VIREMIA; VIROLOGY; VIRUS CARRIER; VIRUS GENOME; VIRUS ISOLATION; VIRUS REPLICATION; WILD TYPE;

ADULT; ALANINE TRANSAMINASE; CARRIER STATE; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULIN M; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES; VIREMIA; VIRUS REPLICATION;

EID: 20844437448     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01048.x     Document Type: Article

References (37)

1. Lee W M. Hepaptitis B virus infection: a review. N Engl J Med 1997; 324: 1733-45.
2. Bergsland E K, Venook A P. Hepatocellular carcinoma. Curr Opin Oncol 2000; 12: 357-61.
3. Ganem D, Prince A M. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
4. Hoofnagle J H, Shafritz D A, Popper H. Chronic type B hepatitis and the "healthy" HBsAg carrier state. Hepatology 1987; 7: 758-63.
5. Lok A S, Heathcote E J, Hoofnagle J H. Management of hepatitis B: 2000 - summary of workshop. Gastroenterology 2001; 120: 1828-53.
6. EASL International Consensus Conference on Hepatitis B Consensus statement. J Hepatol 2003; 39: S3-25.
7. Dragosics B, Ferenci P, Hitchman E, Denk H. Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases. Hepatology 1987; 7: 302-6.
8. de Franchis R, Meucci G, Vecchi M, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993; 118: 191-4.
9. Villeneuve J-P, Desrochers M, Infante-Rivard C, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994; 106: 1000-5.
10. Martinot-Peignoux M, Boyer N, Colombat M, et al. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 2002; 36: 543-6.
11. Koretz R L, Lewin K J, Rebhun D J, Githnick G L. Hepatitis B surface antigen carriers - to biopsy or not to biopsy. Gastroenterology 1978; 75: 860-3.
12. Chu C-J, Hussian M, Lok A S. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002; 36: 1408-15.
13. Chu C-J, Lok A S. Clinical utility in quantifying serum HBV DNA levels using PCR assay. J Hepatol 2002; 36: 549-51.
14. Manesis E K, Papatheodoridis G V, Hadziyannis S J. Serum HBV-DNA levels in inactive hepatitis B virus carriers. Gastroenterology 2002; 122: 2092-3.
15. Hoofnagle J H, Dusheiko G M, Shafer D F, et al. Reactivation of chronic hepatitis b virus infection by cancer chemotherapy. Ann Intern Med 1982; 96: 447-9.
16. Davis G L, Hoofnagle J H. Reactivation of chronic type B hepatitis presenting as acute viral hepatitis. Ann Intern Med 1985; 102: 762-5.
17. Davis G L, Hoofnagle J H. Reactivation of chronic hepatitis B virus infection. Gastroenterology 1987; 92: 2028-31.
18. Cacciola I, Pollicino T, Squadrito G, et al. Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. Hepatology 2000; 31: 507-12.
19. Hunt C M, McGill J, Allen M I, Condreay L D. Clinical relevance of hepatitis B virus mutations. Hepatology 2000; 31: 1037-44.
20. Cacciola I, Cerenzia G, Pollicino T, et al. Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection. J Hepatol 2002; 36: 426-32.
21. Colloredo G, Bellati G, Leandro G, et al. Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray zone" for the evaluation of "borderline" values. J Hepatol 1996; 25: 644-8.
22. Brunetto M R, Giarin E, Oliveri F, et al. Wild-type and e antigen-deficient hepatitis B viruses and corse of chronic hepatitis. Proc Natl Acad Sci USA 1991; 88: 4186-90.
23. Takahashi K, Aoyama K, Ohno N, et al. The precore/core promoter mutant (T1762A1764) of hepatitis B virus: clinical significance and an easy method for detection. J Gen Virol 1995; 76: 3159-64.
24. Gunther S, Piwon N, Iwanska A, Schilling R, Meisel H, Will H. Type, prevalence, and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease. J Virol 1996; 70: 8318-31.
25. Papatheodoritis G V, Hadziyannis S J. Diagnosis and management of pre-core mutant chronic hepatitis B. J Vir Hepat 2001; 8: 311-2.
26. Sjogren M H, Hoofnagle J H. Immunoglobulin M antibody to hepatitis B core antigen in patients with chronic type B hepatitis. Gastroenterology 1985; 89: 252-8.
27. Sjogren M H, Hoofnagle J H, Waggoner J G. Effect of corticosteroid therapy on levels of antibody to hepatitis B core antigen in patients with chronic type B hepatitis. Hepatology 1987; 7: 582-5.
28. Gerlich G H, Uy A, Lambrecht F, Thomssen R. Cut-off levels of IgM antibody against viral core antigen for differentiation of acute, chronic and past hepatitis b virus infection. J Clin Microbiol 1986; 24: 288-93.
29. Brunetto M R, Arrigoni A, Toti M, et al. The diagnostic significance of IgM antibody to hepatitis B core antigen, revisited. Ital J Gastroenterol 1988; 20: 167-70.
30. Brunetto M R, Torriani Cerenzia M, Oliveri F, et al. Monitorino the natural corse and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for IgM anti-HBc. J Hepatol 1993; 19: 431-6.
31. Feinman S V, Overby L R, Berris B, Chau K, Schable C A, Maynard J E. The significance of IgM antibodies to hepatitis B core antigen in hepatitis B carriers and hepatitis B-associated chronic liver disease. Hepatology 1982; 2: 795-9.
32. Schepis F, Verrucchi G, Pollicino T, et al. Outcome of liver disease and response to interferon treatment are not influenced by hepatitis B virus core gene variabilità in children with chronic type B hepatitis. J Hepatol 1997; 26: 765-70.
33. Raimondo G, Meucci G M, Sardo M A, et al. Persistence of "wild-type" and "e-minus" hepatitis B virus infection in chronic healthy HBsAg/anti-HBe positive carriers. J Hepatol 1994; 20: 148-51.
34. Tur-Kaspa R, Klein A, Aharonson S. Hepatitis B virus precore mutants are identical in carriers from various ethnic origins and are associated with a range of liver disease severity. Hepatology 1992; 16: 1338-42.
35. Cacciola I, Cerenzia G, Pollicino T, et al. Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection. J Hepatol 2002; 36: 426-32.
36. Stuver S O. Towards global control of liver cancer? Semin Cancer Biol 1998; 8: 299-306.
37. Hillman M R. Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine 2001; 19: 1837-48.